David R Pearson, EADV 2022: WILLOW study investigating enpatoran for the treatment of systemic and/or cutaneous lupus erythematosus
WILLOW is a phase II, double-blind study investigating enpatoran for the treatment of systemic and/or cutaneous lupus erythematosus (NCT05162586). touchIMMUNOLOGY were delighted to speak with Dr. David R Pearson (University of Minnesota, Minneapolis, MN, USA) about the findings from preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran, and about the aims, eligibility criteria and primary and secondary outcome measures of the WILLOW study.
The abstract ‘Enpatoran: Preclinical Evidence Supporting Glucocorticoid Dose Reduction and Phase II Study Design in Patients with SLE and/or CLE (WILLOW).‘ (Abstract number: 1230) was presented at EADV 2022, 7-10 September, 2022.
Questions
- Could you tell us a little about the preclinical studies evaluating the glucocorticoid-sparing effect of enpatoran? (0:20)
- What were the findings of these studies? (1:23)
- What are the aims, design and eligibility criteria of the WILLOW study? (3:13)
- What are the primary and secondary outcome measures of the study? (3:44)
Disclosures: David R Pearson discloses consulting for Biogen, Inc and receiving grant/ research support from Corbus, EMD Serono, Emerald Health, Kadmon, Pfizer, and Priovant.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EADV meeting 2022.
